CEO Adar Poonawalla said that although they are talking with partners to develop a vaccine, there is no rush as they are assessing the situation.
Average daily COVID-19 vaccinations in February dipped to 2-2.2 million from a high of nearly 8 million in August. The fall, coupled with a decline in the number of coronavirus disease cases, is prompting the Centre to give a push to vaccine exports.
Bharat Biotech is also still to get the World Health Organisation’s approval for Covaxin, an application for which was submitted by the company to the WHO on July 9, 2021.
The delays, announced during an earnings call with investors, are the latest setback for the little-known Maryland company, which was granted up to $1.6 billion from the U.S. federal government last year and whose product has shown robust results in clinical trials.
The government’s decisions are welcome – but it could be several months before vaccine supplies actually improve
India’s tally of over 1.38 crore Covid cases is the second-highest in the world, behind the United States and ahead of Brazil. New mutant strains of the virus have deepened the problem.
Adar Poonawalla said that the Serum Institute of India has already delivered over 100 million doses to the government and is currently producing 65-70 million doses per month.
The new firm will be called Poonawalla Finance.
Prime Minister Narendra Modi is expected to discuss the preparations being made for the COVID-19 vaccination drive with the chief minister.
The subject expert committee of the Central Drugs Standard Control Organisation, India's drug regulator, is likely to meet later this week to examine SII's emergency-use authorisation (EUA) application for Oxford-AstraZeneca’s vaccine.
Coronavirus Vaccine Tracker: Here are all the latest updates on the coronavirus vaccine candidates and their progress.
With this, the collaboration of the three organisations will now produce a total of 20 crore vaccine doses for poorer nations.